Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
RO6839921 binds to MDM2 and inhibits its interaction with p53, preventing degradation of p53, thereby potentially resulting in restoration of wild-type p53 activity and apoptosis of tumor cells (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|RO6839921||RO-6839921||MDM2 Inhibitor 20||RO6839921 is a pegylated prodrug of idasanutlin that binds to MDM2 and inhibits its interaction with p53, preventing degradation of p53, thereby potentially resulting in restoration of wild-type p53 activity and apoptosis of tumor cells (PMID: 31734832, PMID: 32020437).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 wild-type||acute myeloid leukemia||sensitive||RO6839921||Preclinical - Cell line xenograft||Actionable||In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02098967||Phase I||RO6839921||A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.||Completed||USA | CAN||0|